BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference
BeiGene (NASDAQ: BGNE) announced it will change its Nasdaq ticker symbol to 'ONC' on January 2, 2025, alongside its planned name change to BeOne Medicines The new ticker reflects the company's focus on oncology and its 15-year commitment to delivering cancer medicines globally. The CUSIP number and stock codes on Hong Kong and Shanghai exchanges will remain unchanged. Additionally, the company will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, at 1:30 pm PT, with a webcast available on their investor relations websites.
BeiGene (NASDAQ: BGNE) ha annunciato che cambierà il suo simbolo ticker Nasdaq in 'ONC' il 2 gennaio 2025, in concomitanza con il previsto cambiamento di nome in BeOne Medicines. Il nuovo ticker riflette il focus dell'azienda sull'oncologia e il suo impegno di 15 anni nella fornitura di medicinali contro il cancro a livello globale. Il numero CUSIP e i codici azionari sulle borse di Hong Kong e Shanghai rimarranno invariati. Inoltre, l'azienda parteciperà alla 43a Conferenza Sanitaria Annuale J.P. Morgan il 13 gennaio 2025, alle 13:30 PT, con una webcast disponibile sui loro siti web per le relazioni con gli investitori.
BeiGene (NASDAQ: BGNE) anunció que cambiará su símbolo ticker de Nasdaq a 'ONC' el 2 de enero de 2025, junto con su cambio de nombre planeado a BeOne Medicines. El nuevo ticker refleja el enfoque de la compañía en oncología y su compromiso de 15 años para proporcionar medicamentos contra el cáncer a nivel mundial. El número CUSIP y los códigos de acciones en las bolsas de Hong Kong y Shanghái permanecerán sin cambios. Además, la empresa presentará en la 43ª Conferencia Anual de Salud J.P. Morgan el 13 de enero de 2025, a la 1:30 p.m. PT, con una transmisión en vivo disponible en sus sitios web de relaciones con inversionistas.
BeiGene (NASDAQ: BGNE)는 2025년 1월 2일 연내에 주식명칭을 BeOne Medicines로 변경하면서 Nasdaq 티커 기호를 'ONC'로 변경할 것이라고 발표했습니다. 새로운 티커는 회사의 종양학에 대한 집중과 전 세계적으로 암 약물을 제공하기 위한 15년의 약속을 반영합니다. CUSIP 번호 및 홍콩 및 상하이 증권 거래소의 주식 코드는 변경되지 않습니다. 또한 회사는 2025년 1월 13일 오후 1:30 PT에 제43회 연례 J.P. Morgan 헬스케어 회의에서 발표하고, 투자자 관계 웹사이트에서 웹캐스트를 제공할 예정입니다.
BeiGene (NASDAQ: BGNE) a annoncé qu'elle changera son symbole boursier Nasdaq en 'ONC' le 2 janvier 2025, en même temps qu'un changement de nom prévu en BeOne Medicines. Le nouveau symbole reflète l'accent mis par l'entreprise sur l'oncologie et son engagement de 15 ans à fournir des médicaments contre le cancer à l'échelle mondiale. Le numéro CUSIP et les codes boursiers sur les bourses de Hong Kong et de Shanghai demeureront inchangés. De plus, la société se présentera à la 43e Conférence Annuelle sur la Santé J.P. Morgan le 13 janvier 2025, à 13h30 PT, avec un webcast disponible sur leurs sites Web de relations avec les investisseurs.
BeiGene (NASDAQ: BGNE) gab bekannt, dass es sein Nasdaq-Tickersymbol am 2. Januar 2025 in 'ONC' ändern wird, zusammen mit der geplanten Umbenennung in BeOne Medicines. Das neue Tickersymbol spiegelt den Fokus des Unternehmens auf Onkologie und sein 15-jähriges Engagement für die weltweite Bereitstellung von Krebsmedikamenten wider. Die CUSIP-Nummer und die Aktiencodes an den Börsen in Hongkong und Shanghai bleiben unverändert. Darüber hinaus wird das Unternehmen am 43. jährlichen J.P. Morgan Healthcare Conference am 13. Januar 2025 um 13:30 Uhr PT teilnehmen, mit einer Webcast-Verfügbarkeit auf ihren Investor-Relations-Webseiten.
- None.
- None.
“As we enter our 15th year, changing our ticker to ONC reflects our unwavering commitment to leadership in oncology and mission to deliver transformative medicines to cancer patients worldwide,” said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. “This milestone inspires pride in all we have accomplished and fuels our excitement for the future as we advance our innovative hematology franchise and solid tumor pipeline, driving meaningful impact for patients everywhere.”
The Company’s CUSIP number will remain unchanged. In addition, the Company stock codes and stock names for The Stock Exchange of
The Company will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, with a presentation at 1:30 pm PT. The live webcast of the event can be accessed from the Investors section of the Company’s website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. An archived replay will be available for 30 days following the event.
About BeiGene
BeiGene, which plans to change its name to BeOne Medicines, is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of nearly 11,000 colleagues spans five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on LinkedIn, X (formerly known as Twitter), Facebook and Instagram.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene’s leadership in oncology; BeiGene’s ability to advance its hematology franchise and solid tumor pipeline and the related impact on patients; and BeiGene’s plans, commitments, aspirations and goals under the caption “About BeiGene.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeiGene’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeiGene’s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene’s subsequent filings with the
To access BeiGene media resources, please visit our News & Media site.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241223168194/en/
Investor Contact
Liza Heapes
+1 857-302-5663
ir@beigene.com
Media Contact
Kyle Blankenship
+1 667-351-5176
media@beigene.com
Source: BeiGene, Ltd.
FAQ
When will BeiGene (BGNE) change its ticker symbol to ONC?
Will BeiGene's stock codes change on Hong Kong and Shanghai exchanges?
When is BeiGene presenting at the J.P. Morgan Healthcare Conference 2025?
What is BeiGene's new company name going to be?
